AI companies such as OpenAI and Anthropic have long focused on building tools that can write code that will speed up software ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

DNA Ginkgo Bioworks Holdings, Inc.

Abstract: Approximate computing, frequently used in error tolerant applications, aims to achieve higher circuit performances by allowing the possibility of inaccurate ...